End-to-end
Innovation: Accessing Cell lines & Patents
At Ksilink, we believe in the power of collaboration.
We work closely with academic partners, leveraging their scientific and domain expertise to obtain patient-derived cell lines. These cell lines form the basis for our target identification and drug development processes. Our focus is currently on diseases related to the heart and skeletal muscles, as well as the central nervous system. This unique approach allows us to tap into a wealth of knowledge and resources that would otherwise be inaccessible, ensuring that our work is grounded in the latest scientific research.
Illustration: A strategic agreement to jointly invest in a drug discovery portfolio for small molecules and targets discovery.
The Lead Discovery Center contributes:
- Chemical library
- Medicinal chemistry
- DMP/PK
- Industry network
Strategic collaborations
Once we have identified multiple candidate molecules from a human cell-type specific disease model, we collaborate with partners in the biotech or pharma industry. Our goal is to push these molecules into the clinic. This collaborative approach ensures that our findings can be translated into real-world applications, bringing us one step closer to finding cures for diseases. Our unique position as a bridge between academia and industry makes us a valuable partner in drug discovery.